Research Analysts Issue Forecasts for BLSM Q2 Earnings

BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) – Equities researchers at HC Wainwright issued their Q2 2026 earnings per share estimates for BlossomHill Therapeutics in a note issued to investors on Tuesday, September 1st. HC Wainwright analyst R. Burns anticipates that the company will earn ($0.90) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $35.00 target price on the stock. HC Wainwright also issued estimates for BlossomHill Therapeutics’ Q3 2026 earnings at ($0.92) EPS, Q4 2026 earnings at ($0.90) EPS, FY2026 earnings at ($3.71) EPS, Q1 2027 earnings at ($0.86) EPS, Q2 2027 earnings at ($0.77) EPS, Q3 2027 earnings at ($0.69) EPS, Q4 2027 earnings at ($0.69) EPS and FY2027 earnings at ($2.99) EPS.

Other research analysts also recently issued research reports about the company. Wall Street Zen raised BlossomHill Therapeutics to a “hold” rating in a report on Saturday, August 15th. JPMorgan Chase & Co. began coverage on shares of BlossomHill Therapeutics in a research note on Tuesday. They issued an “overweight” rating and a $28.00 price target on the stock. Lifesci Capital started coverage on BlossomHill Therapeutics in a report on Tuesday. They set an “outperform” rating and a $32.00 price target on the stock. Leerink Partners began coverage on shares of BlossomHill Therapeutics in a research note on Tuesday. They set an “outperform” rating and a $36.00 price objective on the stock. Finally, Guggenheim began coverage on BlossomHill Therapeutics in a report on Tuesday. They set a “buy” rating and a $30.00 target price on the stock. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $32.20.

BlossomHill Therapeutics Price Performance

Shares of NASDAQ BLSM opened at $19.38 on Thursday. BlossomHill Therapeutics has a fifty-two week low of $15.25 and a fifty-two week high of $20.61.

Insider Activity at BlossomHill Therapeutics

In other news, Director Orbimed Advisors Llc bought 625,000 shares of the stock in a transaction on Monday, August 10th. The shares were purchased at an average price of $16.00 per share, for a total transaction of $10,000,000.00. Following the completion of the purchase, the director directly owned 2,714,279 shares of the company’s stock, valued at $43,428,464. This trade represents a 29.91% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Vincent Paul Liptak purchased 2,200 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was purchased at an average cost of $16.00 per share, with a total value of $35,200.00. Following the purchase, the general counsel owned 111,412 shares in the company, valued at $1,782,592. This represents a 2.01% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have acquired 1,573,900 shares of company stock worth $25,181,900.

Trending Headlines about BlossomHill Therapeutics

Here are the key news stories impacting BlossomHill Therapeutics this week:

• Positive Sentiment: Several firms recently initiated coverage with bullish ratings and price targets above the current trading level: Leerink Partners rated the shares “Outperform” with a $36 target, HC Wainwright rated them “Buy” with a $35 target, Guggenheim rated them “Buy” with a $30 target, Lifesci Capital rated them “Outperform” with a $32 target, and JPMorgan assigned an “Overweight” rating with a $28 target. The concentration of favorable ratings provides a positive sentiment catalyst for BLSM. Lifesci Capital Initiates Coverage JPMorgan Coverage Initiation
• Positive Sentiment: HC Wainwright’s reiterated “Buy” rating and $35 price objective imply substantial appreciation potential. Its forecasts also show expected losses narrowing from $3.71 per share in fiscal 2026 to $2.99 per share in fiscal 2027, with quarterly losses projected to improve from roughly $0.90–$0.92 to $0.69–$0.86. This improving earnings trajectory could reinforce the bullish case, although the company remains unprofitable. HC Wainwright Estimates and Rating
• Neutral Sentiment: BlossomHill announced upcoming presentations at the 8th Annual RAS-Targeted Drug Development Summit and the H.C. Wainwright Global Investment Conference. The events may give investors additional information about its cancer programs, but the announcement itself does not provide new clinical results. BlossomHill Conference Presentations
• Neutral Sentiment: The company also plans to present updated data from the ongoing Phase 1/2 SOLARA trial of BH-30643, its OMNI-EGFR inhibitor, in EGFR-mutant non-small-cell lung cancer. Investors may view forthcoming data as an important pipeline catalyst, while clinical-stage and loss-making status remain key risks.

BlossomHill Therapeutics Company Profile

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.